Research Faculty

Luke Peterson, Ph.D.
Assistant Research Scientist
Phone: 734/615-4554

Campus address:
UM Comprehensive Cancer Center, Rm 4431
SPC 5936
1500 E. Medical Center Dr., Ann Arbor, MI

Research Interests

The main direction of my research using both in vitro and in vivo models are to investigate strategies of eradicating leukemia stem cells, to understand the molecular mechanisms of such strategy in detail, to assess safety aspects of compounds, further evaluate deregulated molecular pathways involved in leukemia development, and their involvement in resistance or refractory behavior to therapeutic interventions. These studies are addressed using various criteria as outlined below:

Education and Training

July 1992 B.S., Biochemistry, Hogeschool Utrecht, Utrecht, The Netherlands
July 1994 M.S., Biology/Immunology, Utrecht University, The Netherlands
July 2002 Ph.D., Oncology, Manchester University, Manchester, UK
July 2000-Aug 2007 Postdoctoral Associate, The Scripps Research Institute (acute myeloid leukemia)

Honors & Awards

1996-1999 Gordon Piller Leukeamia Research Fund, UK
2003-2005 Skaggs Award, The Scripps Research Institute

Memberships in Professional Societies

2009-present American Society of Hematology (ASH)
2009-present American Associate for the Advancement of Science (AAAS)

Editorial Positions, Boards, and Peer-Review Service

2007-present Ad hoc reviewer for Leukemia
2007-present Ad hoc reviewer for Blood
2011 Grant reviewer for the Association for International Cancer Research
2012-present Ad hoc reviewer for Leukemia and Lymphoma

Selected Peer-Reviewed Publications

  1. Boyapati A, Yan M, Peterson LF, Biggs JR, Le Beau MM, Zhang DE.  A leukemia fusion protein attenuates the spindle checkpoint and promotes aneuploidy.  Blood, 2007 May 1; 109(9):3963-3971. (PMID 17197431)  PMC 1874577

  2. Peterson LF, Yan M, Zhang DE.  The p21Waf1 pathway is involved in blocking leukemogenesis by the t(8;21) fusion protein AML1-ETO. Blood, 2007 May 15; 109(10):4392-4398. (PMID 17284535)  PMC 1885483.

  3. Okumura AJ, Peterson LF, Lo MC, Zhang DE.  Expression of AML/Runx and ETO MTG family members during hematopoietic differentiation of embryonic stem cells. Exp Hematol, 2007 Jun; 35(6):978-988. (PMID 17533052).

  4. Peterson LF, Wang Y, Lo MC, Yan M, Kanbe E, Zhang DE.  The multi-functional cellular adhesion molecule CD44 is regulated by the 8;21 chromosomal translocation. Leukemia, 2007 Sep; 21(9):2010-2019. (PMID 17657222).

  5. Peterson LF, Lo MC, Okumura AJ, Zhang DE.  Inability of RUNX1/AML1 to breach AML1-ETO block of embryonic stem cell definitive hematopoiesis. Blood Cells Mol Dis, 2007 Nov-Dec; 39(3):321-328. (PMID 17692541).

  6. Peterson LF, Boyapati A, Ahn EY, Biggs JR, Okumura AJ, Lo MC, Yan M, Zhang DE. Acute myeloid leukemia with the 8q22;21q22 translocation: secondary mutational events and alternative t(8;21) transcripts. Blood, 2007 Aug 1; 110(3):799-805. (PMID 17412887)  PMC 1924771.

  7. Okumura AJ, Peterson LF, Okumura F, Boyapati A, Zhang DE.  t(8;21)(q22;q22) Fusion proteins preferentially bind to duplicated AML1/RUNX1 DNA-binding sequences to differentially regulate gene expression. Blood, 2008 Aug 15; 112(4):1392-1401. (PMID 18511808) PMC 2515118.

  8. Pene-Dumitrescu T, Peterson LF, Donato NJ, Smithgall TE.  An inhibitor-resistant mutant of Hck protects CML cells against the antiproliferative and apoptotic effects of the broad-spectrum Src family kinase inhibitor A-419259. Oncogene, 2008 Nov 27; 27(56):7055-7069. (PMID 18794796)  PMC 2738638.

  9. Donato NJ, Fang D, Sun H, Giannola D, Peterson LF, Talpaz M.  Targets and effectors of the cellular response to aurora kinase inhibitor MK-0457 (VX-680) in imatinib sensitive and resistant chronic myelogenous leukemia.  Biochem Pharmacol, 2010 Mar 1; 79(5):688-697. (PMID 19874801).

  10. Wu J, Meng F, Ying Y, Peng Z, Daniels L, Bornmann WG, Quintas-Cardama A, Roulston D, Talpaz M, Peterson LF, Donato NJ.  ON012380, a putative BCR-ABL kinase inhibitor with a unique mechanism of action in imatinib-resistant cells. Leukemia, 2010 Apr; 24(4):869-872. (PMID 20111070).

  11. Kapuria V, Peterson LF, Fang D, Bornmann WG, Talpaz M, Donato NJ.  Deubiquitinase inhibition by small-molecule WP1130 triggers aggresome formation and tumor cell apoptosis. Cancer Res, 2010 Nov 15; 70(22):9265-9276. (PMID 21045142).

  12. Donato NJ, Peterson LF.  Chronic myeloid leukemia stem cells and developing therapies. Leuk Lymphoma, 2011 Feb; 52 Suppl 1:60-80. (PMID 21299460).

  13. Sun H, Kapuria V, Peterson LF, Fang D, Bornmann WG, Bartholomeusz G, Talpaz M, Donato NJ. Bcr-Abl ubiquitination and Usp9x inhibition block kinase signaling and promote CML cell apoptosis. Blood 2011 Mar 17; 117(11):3151-3162. (PMID 21248063).

  14. Peterson LF, Mitrikeska E, Giannola D, Lui Y, Sun H, Bixby D, Malek SN, Donato NJ, Wang S, Talpaz M. p53 stabilization induces apoptosis in chronic myeloid leukemia blast crisis cells. Leukemia, 2011 May; 25(5):761-769. (PMID 21350558).

  15. Kapuria V, Peterson LF, Showalter HD, Kirchhoff PD, Talpaz M, Donato NJ.  Protein cross-linking as a novel mechanism of action of a ubiquitin-activating enzyme inhibitor with anti-tumor activity.  Biochem Pharmacol, 2011 Aug 15; 82(4):341-349. (PMID 21621524).

  16. Soliera AR, Mariani SA, Audia A, Lidonnici MR, Addya S, Ferrari-Amorotti G, Cattelani S, Manzotti G, Fragliasso V, Peterson L, Perini G, Holyoake TL, Calabretta B.  Gfi-1 inhibits proliferation and colony formation of p210BCR/ABL-expressing cells via transcriptional repression of STAT 5 and Mcl-1. Leukemia, 2012 Jul; 26(7):1555-1563. (PMID 22285998).

  17. Lo MC, Peterson LF, Yan M, Cong X, Jin F, Shia WJ, Matsuura S, Ahn EY, Komeno Y, Ly M, Ommen HB, Chen IM, Hokland P, Willman CL, Ren B, Zhang DE.  Combined gene expression and DNA occupancy profiling identifies potential therapeutic targets of t(8;21) AML.  Blood, 2012 Aug 16; 120(7):1473-1484. (PMID 22740448)  PMC 3423785.

  18. Lo M-C, Peterson LF. Combined gene expression and dna occupancy profiling as a strategy to identify therapeutic target(s) in t(8;21) acute myeloid leukemia.  Critical Reviews in Eukaryotic Gene Expression, 2013; 23(2):103-113.

Updated Oct 2014